Skip to main content
HYPHENS PHARMA INTERNATIONAL LIMITED logo

HYPHENS PHARMA INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · 1J5 ISIN · SG1EE4000006 SGX Wholesale and retail trade
Open in API
Filings indexed 35 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country SG Singapore
Listing SGX 1J5

About HYPHENS PHARMA INTERNATIONAL LIMITED

https://www.hyphensgroup.com/

HYPHENS PHARMA INTERNATIONAL LIMITED is a specialty pharmaceutical and consumer healthcare group. The company's core activities encompass the marketing and distribution of specialty pharmaceutical products, alongside the development and commercialization of its proprietary dermatological and health supplement brands, such as Ceradan and TDF. Additionally, it operates a medical hypermart and digital platforms. The group maintains a significant presence across ASEAN countries, serving as an exclusive distributor for various products in the region, including Wynzora Cream in Southeast Asia, and extending its proprietary brands like Ceradan to markets including the Middle East.

Recent filings

Filing Released Lang Actions
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Change of Director's Interest - Lim See Wah
Regulatory Filings Classification · 20% confidence The document contains only a placeholder message about updating the PDF viewer and provides no substantive content or references to any specific report type. It does not present any financial statements, meeting materials, or announcements. Under the classification rules, this falls under the fallback category for miscellaneous regulatory or non-content filings: Regulatory Filings (RNS).
2026-06-03 English
Employee Stock Option/ Share Scheme::Notice of Transfer of Treasury Shares
Transaction in Own Shares Classification · 93% confidence The document is a formal announcement by the company’s board regarding the transfer of treasury shares to employees under its performance share plan. It details the number of treasury shares transferred, dates, and percentages, and constitutes a transaction in the company’s own shares (a disposal of treasury shares). This matches the “Transaction in Own Shares” category.
2026-06-02 English
General Announcement::Minutes of the Annual General Meeting held on 28 April 2026
AGM Information Classification · 92% confidence The document is the official minutes of the Company’s Annual General Meeting held on 28 April 2026, detailing the meeting logistics, attendance, resolutions proposed, and polling results. It is not the full annual report or a regulatory filing but a record of the AGM itself. Therefore, it should be classified as AGM Information (Code: AGM-R).
2026-05-22 English
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Change of Director's Interest - Lim See Wah
Regulatory Filings Classification · 12% confidence The document contains no substantive report or detailed announcement content—merely a viewer compatibility notice. This does not fit any specific filing category and serves as a placeholder message. According to fallback rules, this should be classified as a general regulatory or miscellaneous filing (RNS).
2026-05-21 English
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Change of Director's Interest - Lim See Wah
Regulatory Filings Classification · 85% confidence The provided text is merely a generic Adobe Reader placeholder page with instructions to upgrade the PDF viewer. It contains no substantive corporate, financial, or regulatory content. It does not match any specific filing category, so it falls under the fallback “Regulatory Filings” category.
2026-05-20 English
Asset Acquisitions and Disposals::Completion of Proposed Acquisition of the Tranche 3 Sale Shares of 18% in Ardence Pharma Sdn Bhd
M&A Activity Classification · 95% confidence The document is a formal SGX announcement detailing the completion of an acquisition transaction (Tranche 3 completion of 18% share capital in Ardence Pharma), including consideration, financial effects under Chapter 10 of the SGX Catalist Rules, sources of funds, and other transaction-specific disclosures. This is clearly a merger & acquisition activity announcement rather than an annual report, earnings release, or board change notice. Therefore, it is classified as an M&A Activity (Code: TAR).
2026-04-29 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.